AC IMMUNE SA SF-02 Net Assets
AC IMMUNE SA SF-02 net assets. Based on the latest financial reports, AC IMMUNE SA SF-02 (IMR) has net assets worth €35.17 Million EUR (≈ $41.12 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€150.40 Million ≈ $175.83 Million USD) and total liabilities (€115.23 Million ≈ $134.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IMR shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €35.17 Million |
| % of Total Assets | 23.38% |
| Annual Growth Rate | -33.68% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 19.6 |
Net Assets of AC IMMUNE SA SF-02 (2021–2025)
Net assets of AC IMMUNE SA SF-02 from 2021 to 2025. This chart illustrates how AC IMMUNE SA SF-02's net assets have evolved over time, based on quarterly financial data. See net asset quality index of AC IMMUNE SA SF-02 to measure how much of total assets are equity-financed.
Annual Net Assets for AC IMMUNE SA SF-02 (2021–2025)
The table below shows the annual net assets of AC IMMUNE SA SF-02 from 2021 to 2025. For live market cap and overall valuation, see AC IMMUNE SA SF-02 (IMR) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €44.88 Million ≈ $52.47 Million |
-60.02% |
| 2024-12-31 | €112.27 Million ≈ $131.26 Million |
-30.11% |
| 2023-12-31 | €160.64 Million ≈ $187.81 Million |
-4.94% |
| 2022-12-31 | €168.99 Million ≈ $197.57 Million |
-27.15% |
| 2021-12-31 | €231.98 Million ≈ $271.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AC IMMUNE SA SF-02's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23807900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
AC IMMUNE SA SF-02 Net Assets Breakdown (December 2025)
AC IMMUNE SA SF-02 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €483.90 Million | 1078.12% |
| Total Equity | €44.88 Million | 100.00% |
AC IMMUNE SA SF-02 Competitors by Market Cap
The table below lists competitors of AC IMMUNE SA SF-02 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Jingyuan Environmental Protection Co Ltd
SHG:688096
|
$215.53 Million |
|
Evommune, Inc.
NYSE:EVMN
|
$215.58 Million |
|
Kepler Weber S.A
SA:KEPL3
|
$215.63 Million |
|
Arizon RFID Tech (Cayman) Co
TW:6863
|
$215.65 Million |
|
Taaleri Oyj
HE:TAALA
|
$215.49 Million |
|
104 Corporation
TW:3130
|
$215.41 Million |
|
Lyell Immunopharma Inc
NASDAQ:LYEL
|
$215.40 Million |
|
Squirrel Media SA
MC:SQRL
|
$215.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AC IMMUNE SA SF-02's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 112,270,000 to 44,884,000, a change of -67,386,000 (-60.0%).
- Net loss of 70,447,000 reduced equity.
- New share issuances of 6,000 increased equity.
- Other factors increased equity by 3,055,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-70.45 Million | -156.95% |
| Share Issuances | €6.00K | +0.01% |
| Other Changes | €3.06 Million | +6.81% |
| Total Change | €- | -60.02% |
Book Value vs Market Value Analysis
This analysis compares AC IMMUNE SA SF-02's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.67x to 4.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.78 | €1.85 | x |
| 2022-12-31 | €2.02 | €1.85 | x |
| 2023-12-31 | €1.62 | €1.85 | x |
| 2024-12-31 | €1.12 | €1.85 | x |
| 2025-12-31 | €0.44 | €1.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AC IMMUNE SA SF-02 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1971.65%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 3.44x
- Recent ROE (-156.95%) is below the historical average (-61.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -31.47% | 0.00% | 0.00x | 1.13x | €-96.19 Million |
| 2022 | -41.87% | -1798.04% | 0.02x | 1.10x | €-87.65 Million |
| 2023 | -33.76% | -366.41% | 0.08x | 1.14x | €-70.30 Million |
| 2024 | -45.35% | -186.44% | 0.12x | 2.06x | €-62.14 Million |
| 2025 | -156.95% | -1971.65% | 0.02x | 3.44x | €-74.94 Million |
Industry Comparison
This section compares AC IMMUNE SA SF-02's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $82,275,373
- Average return on equity (ROE) among peers: -15.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AC IMMUNE SA SF-02 (IMR) | €35.17 Million | -31.47% | 3.28x | $215.51 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-294.00K | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $141.29 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-223.84 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $125.74 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $218.97 Million | -16.25% | 0.03x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $699.56 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more